Sphingomyelin in High-Density Lipoproteins: Structural Role and Biological Function

International Journal of Molecular Sciences

Volumn 14, Issue 4, 2013, Pages 7716-7741

  Martínez Beamonte, Roberto ^a,b   Lou Bonafonte, Jose M ^b,c   Martínez Gracia, María V ^b   Osada, Jesús ^a,b  

^a INSTITUTO DE INVESTIGACIÓN SANITARIA ARAGÓN IIS ARAGÓN   (Spain)

^b Instituto de Salud Carlos III   (Spain)

^c UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

High density lipoproteins; Phospholipids; Sphingomyelin

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; ATORVASTATIN; CAPTOPRIL; CHOLESTEROL; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; HYDROCHLOROTHIAZIDE; IBUPROFEN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PHOSPHOLIPASE A2 GROUP V; RALOXIFENE; SCAVENGER RECEPTOR BI; SPHINGOMYELIN; HIGH DENSITY LIPOPROTEIN SPHINGOMYELIN;

AGING; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; DISEASE ASSOCIATION; DRUG EFFECT; ENZYME ACTIVITY; GENDER; HUMAN; HYPERTENSION; INTRACELLULAR TRANSPORT; LIFESTYLE; LIPID METABOLISM; NIEMANN PICK DISEASE; NONHUMAN; PHOSPHOLIPID TRANSFER; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN TRANSPORT; REVIEW; SEX DIFFERENCE; STRUCTURE ACTIVITY RELATION; TANGIER DISEASE; ACTIVE TRANSPORT; ANIMAL; CARDIOVASCULAR DISEASES; CHEMISTRY; DIET THERAPY; METABOLISM; NIEMANN-PICK DISEASES; PATHOLOGY;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CARDIOVASCULAR DISEASES; HUMANS; LIPID METABOLISM; LIPOPROTEINS, HDL; NIEMANN-PICK DISEASES; SPHINGOMYELINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84876331521     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14047716     Document Type: Review

References (182)

1. Vaisar, T.; Pennathur, S.; Green, P.S.; Gharib, S.A.; Hoofnagle, A.N.; Cheung, M.C.; Byun, J.; Vuletic, S.; Kassim, S.; Singh, P.; et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J. Clin. Invest. 2007, 117, 746-756.
2. Lou-Bonafonte, J.M.; Fito, M.; Covas, M.I.; Farras, M.; Osada, J. HDL-related mechanisms of olive oil protection in cardiovascular disease. Curr. Vasc. Pharmacol. 2012, 10, 392-409.
3. Gotto, A.M., Jr. High-density lipoproteins: Biochemical and metabolic factors. Am. J. Cardiol. 1983, 52, 2B-4B.
4. Rosenson, R.S.; Brewer, H.B., Jr.; Chapman, M.J.; Fazio, S.; Hussain, M.M.; Kontush, A.; Krauss, R.M.; Otvos, J.D.; Remaley, A.T.; Schaefer, E.J. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin. Chem. 2011, 57, 392-410.
5. Kontush, A.; Therond, P.; Zerrad, A.; Couturier, M.; Negre-Salvayre, A.; de Souza, J.A.; Chantepie, S.; Chapman, M.J. Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: Relevance to antiapoptotic and antioxidative activities. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 1843-1849.
6. Hofer, G.; Lichtenberg, D.; Kostner, G.M.; Hermetter, A. Oxidation of fluorescent glycero- and sphingophospholipids in human plasma lipoproteins: Alkenylacyl subclasses are preferred targets. Clin. Biochem. 1996, 29, 445-450.
7. Chong, C.P.; Lin, T.Y.; Chang, C.L.; Yang, Y.L.; Tsai, M.H.; Yu, Y.S.; Liu, M.Y. Micellar electrokinetic chromatography profiles of human high-density lipoprotein phospholipids. Electrophoresis 2011, 32, 1241-1251.
8. Khovidhunkit, W.; Kim, M.S.; Memon, R.A.; Shigenaga, J.K.; Moser, A.H.; Feingold, K.R.; Grunfeld, C. Effects of infection and inflammation on lipid and lipoprotein metabolism: Mechanisms and consequences to the host. J. Lipid Res. 2004, 45, 1169-1196.
9. Navab, M.; Reddy, S.T.; van Lenten, B.J.; Anantharamaiah, G.M.; Fogelman, A.M. The role of dysfunctional HDL in atherosclerosis. J. Lipid Res. 2009, 50, S145-S149.
10. Hammad, S.M.; Pierce, J.S.; Soodavar, F.; Smith, K.J.; Al Gadban, M.M.; Rembiesa, B.; Klein, R.L.; Hannun, Y.A.; Bielawski, J.; Bielawska, A. Blood sphingolipidomics in healthy humans: Impact of sample collection methodology. J. Lipid Res. 2010, 51, 3074-3087.
11. Rodriguez, C.; Gonzalez-Diez, M.; Badimon, L.; Martinez-Gonzalez, J. Sphingosine-1-phosphate: A bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin. Thromb. Haemost. 2009, 101, 665-673.
12. Hoofnagle, A.N.; Vaisar, T.; Mitra, P.; Chait, A. HDL lipids and insulin resistance. Curr. Diab. Rep. 2010, 10, 78-86.
13. Yetukuri, L.; Soderlund, S.; Koivuniemi, A.; Seppanen-Laakso, T.; Niemela, P.S.; Hyvonen, M.; Taskinen, M.R.; Vattulainen, I.; Jauhiainen, M.; Oresic, M. Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol. J. Lipid Res. 2010, 51, 2341-2351.
14. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; The, P.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement. PLoS Med. 2009, 6, e1000097.
15. Skipski, V.P.; Barclay, M.; Barclay, R.K.; Fetzer, V.A.; Good, J.J.; Archibald, F.M. Lipid composition of human serum lipoproteins. Biochem. J. 1967, 104, 340-352.
16. Daerr, W.H.; Greten, H. In vitro modulation of the distribution of normal human plasma high density lipoprotein subfractions through the lecithin: Cholesterol acyltransferase reaction. Biochim. Biophys. Acta 1982, 710, 128-133.
17. Darr, W.H.; Windler, E.E.; Stephan, K.U.; Walli, A.K.; Greten, H. Characterization and catabolism of rat very high density lipoproteins. J. Lipid Res. 1985, 26, 672-683.
18. Davidson, W.S.; Sparks, D.L.; Lund-Katz, S.; Phillips, M.C. The molecular basis for the difference in charge between pre-beta- and alpha-migrating high density lipoproteins. J. Biol. Chem. 1994, 269, 8959-8965.
19. Marques-Vidal, P.; Jauhiainen, M.; Metso, J.; Ehnholm, C. Transformation of high density lipoprotein 2 particles by hepatic lipase and phospholipid transfer protein. Atherosclerosis 1997, 133, 87-95.
20. Maldonado, E.N.; Casanave, E.B.; Aveldano, M.I. Major plasma lipids and fatty acids in four HDL mammals. Comp. Biochem. Physiol. Part A 2002, 132, 297-303.
21. Blaton, V.; Vercaemst, R.; Rosseneu, M.; Mortelmans, J.; Jackson, R.L.; Gotto, A.M., Jr.; Peeters, H. Characterization of baboon plasma high-density lipoproteins and of their major apoproteins. Biochemistry 1977, 16, 2157-2163.
22. McConathy, W.J.; Alaupovic, P. Studies on the isolation and partial characterization of apolipoprotein D and lipoprotein D of human plasma. Biochemistry 1976, 15, 515-520.
23. Krimbou, L.; Tremblay, M.; Jacques, H.; Davignon, J.; Cohn, J.S. In vitro factors affecting the concentration of gamma-LpE in human plasma. J. Lipid Res. 1998, 39, 861-872.
24. Duverger, N.; Ghalim, N.; Theret, N.; Fruchart, J.C.; Castro, G. Lipoproteins containing apolipoprotein A-IV: Composition and relation to cholesterol esterification. Biochim. Biophys. Acta 1994, 1211, 23-28.
25. Atmeh, R.F.; Kana'an, B.M.; Massad, T.T. Isolation of high density lipoprotein subclasses by electrofiltration and their chemical components. Prep. Biochem. Biotechnol. 2009, 39, 248-265.
26. Nanjee, M.N.; Cooke, C.J.; Olszewski, W.L.; Miller, N.E. Lipid and apolipoprotein concentrations in prenodal leg lymph of fasted humans. Associations with plasma concentrations in normal subjects, lipoprotein lipase deficiency, and LCAT deficiency. J. Lipid Res. 2000, 41, 1317-1327.
27. Sloop, C.H.; Dory, L.; Roheim, P.S. Interstitial fluid lipoproteins. J. Lipid Res. 1987, 28, 225-237.
28. Worgall, T.S. Sphingolipid synthetic pathways are major regulators of lipid homeostasis. Adv. Exp. Med. Biol. 2011, 721, 139-148.
29. Hussain, M.M.; Jin, W.; Jiang, X.C. Mechanisms involved in cellular ceramide homeostasis. Nutr. Metab. 2012, 9, 71.
30. Maric, J.; Kiss, R.S.; Franklin, V.; Marcel, Y.L. Intracellular lipidation of newly synthesized apolipoprotein A-I in primary murine hepatocytes. J. Biol. Chem. 2005, 280, 39942-39949.
31. Subbaiah, P.V.; Gesquiere, L.R.; Wang, K. Regulation of the selective uptake of cholesteryl esters from high density lipoproteins by sphingomyelin. J. Lipid Res. 2005, 46, 2699-2705.
32. Bielicki, J.K.; Johnson, W.J.; Glick, J.M.; Rothblat, G.H. Efflux of phospholipid from fibroblasts with normal and elevated levels of cholesterol. Biochim. Biophys. Acta 1991, 1085, 7-14.
33. Zhang, W.; Asztalos, B.; Roheim, P.S.; Wong, L. Characterization of phospholipids in pre-alpha HDL: Selective phospholipid efflux with apolipoprotein A-I. J. Lipid Res. 1998, 39, 1601-1607.
34. Sorci-Thomas, M.G.; Owen, J.S.; Fulp, B.; Bhat, S.; Zhu, X.; Parks, J.S.; Shah, D.; Jerome, W.G.; Gerelus, M.; Zabalawi, M.; et al. Nascent high density lipoproteins formed by ABCA1 resemble lipid rafts and are structurally organized by three apoA-I monomers. J. Lipid Res. 2012, 53, 1890-1909.
35. Choi, H.Y.; Karten, B.; Chan, T.; Vance, J.E.; Greer, W.L.; Heidenreich, R.A.; Garver, W.S.; Francis, G.A. Impaired ABCA1-dependent lipid efflux and hypoalphalipoproteinemia in human Niemann-Pick type C disease. J. Biol. Chem. 2003, 278, 32569-32577.
36. Toledo, J.D.; Cabaleiro, L.V.; Garda, H.A.; Gonzalez, M.C. Effect of reconstituted discoidal high-density lipoproteins on lipid mobilization in RAW 264.7 and CHOK1 cells. J. Cell. Biochem. 2011, 113, 1208-1216.
37. Savion, N.; Greemland, M.; Kotev-Emeth, S.; Thilo-Korner, D.G. Metabolism of cholesterol and phospholipids in cultured human vascular smooth muscle cells: Differences between artery and vein-derived cells and the effect of oxygen partial pressure. Eur. J. Cell. Biol. 1991, 55, 305-311.
38. Francis, G.A.; Tsujita, M.; Terry, T.L. Apolipoprotein AI efficiently binds to and mediates cholesterol and phospholipid efflux from human but not rat aortic smooth muscle cells. Biochemistry 1999, 38, 16315-16322.
39. Massey, J.B.; Hickson-Bick, D.; Via, D.P.; Gotto, A.M., Jr.; Pownall, H.J. Fluorescence assay of the specificity of human plasma and bovine liver phospholipid transfer proteins. Biochim. Biophys. Acta 1985, 835, 124-131.
40. Schifferer, R.; Liebisch, G.; Bandulik, S.; Langmann, T.; Dada, A.; Schmitz, G. ApoA-I induces a preferential efflux of monounsaturated phosphatidylcholine and medium chain sphingomyelin species from a cellular pool distinct from HDL(3) mediated phospholipid efflux. Biochim. Biophys. Acta 2007, 1771, 853-863.
41. Fukuda, M.; Nakano, M.; Sriwongsitanont, S.; Ueno, M.; Kuroda, Y.; Handa, T. Spontaneous reconstitution of discoidal HDL from sphingomyelin-containing model membranes by apolipoprotein A-I. J. Lipid Res. 2007, 48, 882-889.
42. Sparks, D.L.; Frank, P.G.; Neville, T.A. Effect of the surface lipid composition of reconstituted LPA-I on apolipoprotein A-I structure and lecithin: Cholesterol acyltransferase activity. Biochim. Biophys. Acta 1998, 1390, 160-172.
43. Rye, K.A.; Hime, N.J.; Barter, P.J. The influence of sphingomyelin on the structure and function of reconstituted high density lipoproteins. J. Biol. Chem. 1996, 271, 4243-4250.
44. Lottin, H.; Motta, C.; Simard, G. Differential effects of glycero- and sphingo-phospholipolysis on human high-density lipoprotein fluidity. Biochim. Biophys. Acta 1996, 1301, 127-132.
45. Slotte, J.P.; Gronberg, L. Oxidation of cholesterol in low density and high density lipoproteins by cholesterol oxidase. J. Lipid Res. 1990, 31, 2235-2242.
46. Subbaiah, P.V.; Subramanian, V.S.; Wang, K. Novel physiological function of sphingomyelin in plasma. Inhibition of lipid peroxidation in low density lipoproteins. J. Biol. Chem. 1999, 274, 36409-36414.
47. Assmann, G.; Sokoloski, E.A.; Brewer, H.B., Jr. 31P nuclear magnetic resonance spectroscopy of native and recombined lipoproteins. Proc. Natl. Acad. Sci. USA 1974, 71, 549-553.
48. Assmann, G.; Highet, R.J.; Sokoloski, E.A.; Brewer, H.B., Jr. 13C nuclear magnetic resonance spectroscopy of native and recombined lipoproteins. Proc. Natl. Acad. Sci. USA 1974, 71, 3701-3705.
49. Stoffel, W.; Metz, P. Chemical studies on the structure of human serum high-density lipoprotein (HDL). Photochemical crosslinking of azido-labelled lipids in HDL. Hoppe-Seyler's. Z. Physiol. Chem. 1982, 363, 19-31.
50. Tam, S.P.; Breckenridge, W.C. Apolipoprotein and lipid distribution between vesicles and HDL-like particles formed during lipolysis of human very low density lipoproteins by perfused rat heart. J. Lipid Res. 1983, 24, 1343-1357.
51. Stoffel, W.; Darr, W.; Salm, K.P. Lipid-protein interactions between human apolipoprotein A-I and defined sphingomyelin species. A 13C-NMR spectroscopic study. Hoppe-Seyler's Z. Physiol. Chem. 1977, 358, 1-11.
52. Stoffel, W.; Darr, W.; Salm, K.P. Chemical proof of lipid-protein interactions by crosslinking photosensitive lipids to apoproteins. Intermolecular cross-linkage between high-density apolipoprotein A-I and lecithins and sphingomyelins. Hoppe.-Seyler's Z. Physiol. Chem. 1977, 358, 453-462.
53. Swaney, J.B. Reconstitution of apolipoprotein A-I from human high density lipoprotein with bovine brain sphingomyelin. J. Biol. Chem. 1983, 258, 1254-1259.
54. Assmann, G.; Brewer, H.B., Jr. Lipid-protein interactions in high density lipoproteins. Proc. Natl. Acad. Sci. USA 1974, 71, 989-993.
55. Stoffel, W.; Zierenberg, O.; Tunggal, B.; Schreiber, E. 13C nuclear magnetic resonance spectroscopic evidence for hydrophobic lipid-protein interactions in human high density lipoproteins. Proc. Natl. Acad. Sci. USA 1974, 71, 3696-3700.
56. Ibdah, J.A.; Lund-Katz, S.; Phillips, M.C. Molecular packing of high-density and low-density lipoprotein surface lipids and apolipoprotein A-I binding. Biochemistry 1989, 28, 1126-1133.
57. Forte, T.M.; Bielicki, J.K.; Goth-Goldstein, R.; Selmek, J.; McCall, M.R. Recruitment of cell phospholipids and cholesterol by apolipoproteins A-II and A-I: Formation of nascent apolipoprotein-specific HDL that differ in size, phospholipid composition, and reactivity with LCAT. J. Lipid Res. 1995, 36, 148-157.
58. Molotkovsky, J.G.; Manevich, Y.M.; Gerasimova, E.N.; Molotkovskaya, I.M.; Polessky, V.A.; Bergelson, L.D. Differential study of phosphatidylcholine and sphingomyelin in human high-density lipoproteins with lipid-specific fluorescent probes. Eur. J. Biochem. 1982, 122, 573-579.
59. Lindholm, E.M.; Bielicki, J.K.; Curtiss, L.K.; Rubin, E.M.; Forte, T.M. Deletion of amino acids Glu146->Arg160 in human apolipoprotein A-I (ApoA-ISeattle) alters lecithin: Cholesterol acyltransferase activity and recruitment of cell phospholipid. Biochemistry 1998, 37, 4863-4868.
60. Fox, T.E.; Bewley, M.C.; Unrath, K.A.; Pedersen, M.M.; Anderson, R.E.; Jung, D.Y.; Jefferson, L.S.; Kim, J.K.; Bronson, S.K.; Flanagan, J.M.; et al. Circulating sphingolipid biomarkers in models of type 1 diabetes. J. Lipid Res. 2011, 52, 509-517.
61. Laurila, P.P.; Surakka, I.; Sarin, A.P.; Yetukuri, L.; Hyotylainen, T.; Soderlund, S.; Naukkarinen, J.; Tang, J.; Kettunen, J.; Mirel, D.B.; et al. Genomic, transcriptomic, and lipidomic profiling highlights the role of inflammation in individuals with low high-density lipoprotein cholesterol. Arterioscler. Thromb. Vasc. Biol. 2013, 33, 847-857.
62. Kuksis, A.; Myher, J.J.; Geher, K.; Breckenridge, W.C.; Jones, G.J.; Little, J.A. Lipid class and molecular species interrelationships among plasma lipoproteins of normolipemic subjects. J. Chromatogr. 1981, 224, 1-23.
63. Myher, J.J.; Kuksis, A.; Breckenridge, W.C.; Little, J.A. Differential distribution of sphingomyelins among plasma lipoprotein classes. Can. J. Biochem. 1981, 59, 626-636.
64. Kuksis, A.; Myher, J.J.; Geher, K.; Breckenridge, W.C.; Little, J.A. Lipid class and molecular species interrelationships among plasma lipoproteins of type III and type IV hyperlipemic subjects. J. Chromatogr. 1982, 230, 231-252.
65. Breckenridge, W.C.; Dolphin, P.J.; Tan, M.H. Distribution of the molecular species of phospholipids in human umbilical cord blood. Lipids 1984, 19, 337-340.
66. Wu, C.Y.; Peng, Y.N.; Chiu, J.H.; Ho, Y.L.; Chong, C.P.; Yang, Y.L.; Liu, M.Y. Characterization of in vitro modified human high-density lipoprotein particles and phospholipids by capillary zone electrophoresis and LC ESI-MS. J. Chromatogr. B 2009, 877, 3495-3505.
67. Stubiger, G.; Aldover-Macasaet, E.; Bicker, W.; Sobal, G.; Willfort-Ehringer, A.; Pock, K.; Bochkov, V.; Widhalm, K.; Belgacem, O. Targeted profiling of atherogenic phospholipids in human plasma and lipoproteins of hyperlipidemic patients using MALDI-QIT-TOF-MS/MS. Atherosclerosis 2012, 224, 177-186.
68. Fernando-Warnakulasuriya, G.J.; Eckerson, M.L.; Clark, W.A.; Wells, M.A. Lipoprotein metabolism in the suckling rat: Characterization of plasma and lymphatic lipoproteins. J. Lipid Res. 1983, 24, 1626-1638.
69. Bentejac, M.; Bugaut, M.; Delachambre, M.C.; Lecerf, J. Utilization of high-density lipoprotein sphingomyelin by the developing and mature brain in the rat. J. Neurochem. 1989, 52, 1495-1500.
70. Bentejac, M.; Bugaut, M.; Delachambre, M.C.; Lecerf, J. Time-course of utilization of (stearic or lignoceric acid)sphingomyelin from high-density lipoprotein by rat tissues. Biochim. Biophys. Acta 1990, 1043, 134-142.
71. Bamberger, M.; Lund-Katz, S.; Phillips, M.C.; Rothblat, G.H. Mechanism of the hepatic lipase induced accumulation of high-density lipoprotein cholesterol by cells in culture. Biochemistry 1985, 24, 3693-3701.
72. Engelmann, B.; Kogl, C.; Kulschar, R.; Schaipp, B. Transfer of phosphatidylcholine, phosphatidylethanolamine and sphingomyelin from low- and high-density lipoprotein to human platelets. Biochem. J. 1996, 315, 781-789.
73. Bentejac, M.; Lecerf, J.; Bugaut, M.; Delachambre, M.C. Turnover and uptake of double-labelled high-density lipoprotein sphingomyelin in the adult rat. Biochim. Biophys. Acta 1988, 959, 349-360.
74. Bentejac, M.; Bugaut, M.; Delachambre, M.C.; Lecerf, J. Metabolic fate of sphingomyelin of high-density lipoprotein in rat plasma. Lipids 1990, 25, 653-660.
75. Illingworth, D.R.; Portman, O.W. Exchange of phospholipids between low and high density lipoproteins of squirrel monkeys. J. Lipid Res. 1972, 13, 220-227.
76. Fournier, N.; Paul, J.L.; Atger, V.; Cogny, A.; Soni, T.; de la Llera-Moya, M.; Rothblat, G.; Moatti, N. HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum. Arterioscler. Thromb. Vasc. Biol. 1997, 17, 2685-2691.
77. Horter, M.J.; Sondermann, S.; Reinecke, H.; Bogdanski, J.; Woltering, A.; Kerber, S.; Breithardt, G.; Assmann, G.; Von Eckardstein, A. Associations of HDL phospholipids and paraoxonase activity with coronary heart disease in postmenopausal women. Acta Physiol. Scand. 2002, 176, 123-130.
78. Hergenc, G.; Onat, A.; Sari, I.; Yazici, M.; Eryonucu, B.; Can, G. Serum total and high-density lipoprotein phospholipid levels in a population-based study and relationship to risk of metabolic syndrome and coronary disease. Angiology 2008, 59, 26-35.
79. Stein, Y.; Glangeaud, M.C.; Fainaru, M.; Stein, O. The removal of cholesterol from aortic smooth muscle cells in culture and Landschutz ascites cells by fractions of human high-density apolipoprotein. Biochim. Biophys. Acta 1975, 380, 106-118.
80. Stein, O.; Vanderhoek, J.; Stein, Y. Cholesterol content and sterol synthesis in human skin fibroblasts and rat aortic smooth muscle cells exposed to lipoprotein-depleted serum and high density apolipoprotein/phospholipid mixtures. Biochim. Biophys. Acta 1976, 431, 347-358.
81. Stein, O.; Coetzee, G.A.; Stein, Y. Modulation of cytoplasmic cholesteryl ester of smooth muscle cells in culture derived from rat, rabbit and bovine aorta. Biochim. Biophys. Acta 1980, 620, 538-549.
82. Stein, O.; Dabach, Y.; Hollander, G.; Halperin, G.; Oette, K.; Stein, Y. Cholesterol removal by peritoneal lavage with phospholipid-HDL apoprotein mixtures in hypercholesterolemic hamsters. Biochim. Biophys. Acta 1989, 1006, 144-146.
83. Zhao, Y.; Sparks, D.L.; Marcel, Y.L. Effect of the apolipoprotein A-I and surface lipid composition of reconstituted discoidal HDL on cholesterol efflux from cultured fibroblasts. Biochemistry 1996, 35, 16510-16518.
84. Swaney, J.B. Membrane cholesterol uptake by recombinant lipoproteins. Chem. Phys. Lipids 1985, 37, 317-327.
85. Jian, B.; de la Llera-Moya, M.; Royer, L.; Rothblat, G.; Francone, O.; Swaney, J.B. Modification of the cholesterol efflux properties of human serum by enrichment with phospholipid. J. Lipid Res. 1997, 38, 734-744.
86. Haidar, B.; Mott, S.; Boucher, B.; Lee, C.Y.; Marcil, M.; Genest, J., Jr. Cellular cholesterol efflux is modulated by phospholipid-derived signaling molecules in familial HDL deficiency/Tangier disease fibroblasts. J. Lipid Res. 2001, 42, 249-257.
87. Ma, C.I.; Beckstead, J.A.; Thompson, A.; Hafiane, A.; Wang, R.H.; Ryan, R.O.; Kiss, R.S. Tweaking the cholesterol efflux capacity of reconstituted HDL. Biochem. Cell. Biol. 2012, 90, 636-645.
88. Kobayashi, A.; Takanezawa, Y.; Hirata, T.; Shimizu, Y.; Misasa, K.; Kioka, N.; Arai, H.; Ueda, K.; Matsuo, M. Efflux of sphingomyelin, cholesterol, and phosphatidylcholine by ABCG1. J. Lipid Res. 2006, 47, 1791-1802.
89. Kimura, Y.; Morita, S.Y.; Matsuo, M.; Ueda, K. Mechanism of multidrug recognition by MDR1/ABCB1. Cancer Sci. 2007, 98, 1303-1310.
90. Liu, L.; Bortnick, A.E.; Nickel, M.; Dhanasekaran, P.; Subbaiah, P.V.; Lund-Katz, S.; Rothblat, G.H.; Phillips, M.C. Effects of apolipoprotein A-I on ATP-binding cassette transporter A1-mediated efflux of macrophage phospholipid and cholesterol: Formation of nascent high density lipoprotein particles. J. Biol. Chem. 2003, 278, 42976-42984.
91. Hirayama, H.; Kimura, Y.; Kioka, N.; Matsuo, M.; Ueda, K. ATPase activity of human ABCG1 is stimulated by cholesterol and sphingomyelin. J. Lipid Res. 2013, 54, 496-502.
92. Sano, O.; Kobayashi, A.; Nagao, K.; Kumagai, K.; Kioka, N.; Hanada, K.; Ueda, K.; Matsuo, M. Sphingomyelin-dependence of cholesterol efflux mediated by ABCG1. J. Lipid Res. 2007, 48, 2377-2384.
93. Miller, M.; Zhan, M. Genetic determinants of low high-density lipoprotein cholesterol. Curr. Opin. Cardiol. 2004, 19, 380-384.
94. Marmillot, P.; Patel, S.; Lakshman, M.R. Reverse cholesterol transport is regulated by varying fatty acyl chain saturation and sphingomyelin content in reconstituted high-density lipoproteins. Metabolism 2007, 56, 251-259.
95. Sanchez, S.A.; Tricerri, M.A.; Gratton, E. Interaction of high density lipoprotein particles with membranes containing cholesterol. J. Lipid Res. 2007, 48, 1689-1700.
96. Gold, J.C.; Phillips, M.C. Effects of membrane lipid composition on the kinetics of cholesterol exchange between lipoproteins and different species of red blood cells. Biochim. Biophys. Acta 1990, 1027, 85-92.
97. Slotte, J.P.; Tenhunen, J.; Porn, I. Effects of sphingomyelin degradation on cholesterol mobilization and efflux to high-density lipoproteins in cultured fibroblasts. Biochim. Biophys. Acta 1990, 1025, 152-156.
98. Porn, M.I.; Ares, M.P.; Slotte, J.P. Degradation of plasma membrane phosphatidylcholine appears not to affect the cellular cholesterol distribution. J. Lipid Res. 1993, 34, 1385-1392.
99. Ito, J.; Nagayasu, Y.; Yokoyama, S. Cholesterol-sphingomyelin interaction in membrane and apolipoprotein-mediated cellular cholesterol efflux. J. Lipid Res. 2000, 41, 894-904.
100. Ito, J.; Nagayasu, Y.; Ueno, S.; Yokoyama, S. Apolipoprotein-mediated cellular lipid release requires replenishment of sphingomyelin in a phosphatidylcholine-specific phospholipase C-dependent manner. J. Biol. Chem. 2002, 277, 44709-44714.
101. Nagao, K.; Takahashi, K.; Hanada, K.; Kioka, N.; Matsuo, M.; Ueda, K. Enhanced apoA-I-dependent cholesterol efflux by ABCA1 from sphingomyelin-deficient Chinese hamster ovary cells. J. Biol. Chem. 2007, 282, 14868-14874.
102. Yamauchi, Y.; Hayashi, M.; Abe-Dohmae, S.; Yokoyama, S. Apolipoprotein A-I activates protein kinase C alpha signaling to phosphorylate and stabilize ATP binding cassette transporter A1 for the high density lipoprotein assembly. J. Biol. Chem. 2003, 278, 47890-47897.
103. Takahashi, K.; Kimura, Y.; Kioka, N.; Matsuo, M.; Ueda, K. Purification and ATPase activity of human ABCA1. J. Biol. Chem. 2006, 281, 10760-10768.
104. Panousis, C.G.; Zuckerman, S.H. Interferon-gamma induces downregulation of Tangier disease gene (ATP-binding-cassette transporter 1) in macrophage-derived foam cells. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 1565-1571.
105. Tamehiro, N.; Zhou, S.; Okuhira, K.; Benita, Y.; Brown, C.E.; Zhuang, D.Z.; Latz, E.; Hornemann, T.; von Eckardstein, A.; Xavier, R.J.; et al. SPTLC1 binds ABCA1 to negatively regulate trafficking and cholesterol efflux activity of the transporter. Biochemistry 2008, 47, 6138-6147.
106. Allen, T.M. A study of phospholipid interactions between high-density lipoproteins and small unilamellar vesicles. Biochim. Biophys. Acta 1981, 640, 385-397.
107. Sweeny, S.A.; Jonas, A. Substrate specificity of human plasma phospholipid transfer protein. Biochim. Biophys. Acta 1985, 835, 279-290.
108. Singh, D.K.; Gesquiere, L.R.; Subbaiah, P.V. Role of sphingomyelin and ceramide in the regulation of the activity and fatty acid specificity of group V secretory phospholipase A2. Arch. Biochem. Biophys. 2007, 459, 280-287.
109. Subbaiah, P.V.; Liu, M. Role of sphingomyelin in the regulation of cholesterol esterification in the plasma lipoproteins. Inhibition of lecithin-cholesterol acyltransferase reaction. J. Biol. Chem. 1993, 268, 20156-20163.
110. Subbaiah, P.V.; Jiang, X.C.; Belikova, N.A.; Aizezi, B.; Huang, Z.H.; Reardon, C.A. Regulation of plasma cholesterol esterification by sphingomyelin: Effect of physiological variations of plasma sphingomyelin on lecithin-cholesterol acyltransferase activity. Biochim. Biophys. Acta 2012, 1821, 908-913.
111. Park, T.S.; Panek, R.L.; Rekhter, M.D.; Mueller, S.B.; Rosebury, W.S.; Robertson, A.; Hanselman, J.C.; Kindt, E.; Homan, R.; Karathanasis, S.K. Modulation of lipoprotein metabolism by inhibition of sphingomyelin synthesis in ApoE knockout mice. Atherosclerosis 2006, 189, 264-272.
112. Gesquiere, L.; Cho, W.; Subbaiah, P.V. Role of group IIa and group V secretory phospholipases A(2) in the metabolism of lipoproteins. Substrate specificities of the enzymes and the regulation of their activities by sphingomyelin. Biochemistry 2002, 41, 4911-4920.
113. Singh, D.K.; Subbaiah, P.V. Modulation of the activity and arachidonic acid selectivity of group X secretory phospholipase A2 by sphingolipids. J. Lipid Res. 2007, 48, 683-692.
114. Nilsson, A.; Duan, R.D. Absorption and lipoprotein transport of sphingomyelin. J. Lipid Res. 2006, 47, 154-171.
115. Chajek, T.; Aron, L.; Fielding, C.J. Interaction of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in the transport of cholesteryl ester into sphingomyelin liposomes. Biochemistry 1980, 19, 3673-3677.
116. Bolin, D.J.; Jonas, A. Sphingomyelin inhibits the lecithin-cholesterol acyltransferase reaction with reconstituted high density lipoproteins by decreasing enzyme binding. J. Biol. Chem. 1996, 271, 19152-19158.
117. Lee, J.Y.; Badeau, R.M.; Mulya, A.; Boudyguina, E.; Gebre, A.K.; Smith, T.L.; Parks, J.S. Functional LCAT deficiency in human apolipoprotein A-I transgenic, SR-BI knockout mice. J. Lipid Res. 2007, 48, 1052-1061.
118. Rodrigueza, W.V.; Thuahnai, S.T.; Temel, R.E.; Lund-Katz, S.; Phillips, M.C.; Williams, D.L. Mechanism of scavenger receptor class B type I-mediated selective uptake of cholesteryl esters from high density lipoprotein to adrenal cells. J. Biol. Chem. 1999, 274, 20344-20350.
119. Rhainds, D.; Bourgeois, P.; Bourret, G.; Huard, K.; Falstrault, L.; Brissette, L. Localization and regulation of SR-BI in membrane rafts of HepG2 cells. J. Cell. Sci. 2004, 117, 3095-3105.
120. Thuahnai, S.T.; Lund-Katz, S.; Williams, D.L.; Phillips, M.C. Scavenger receptor class B, type I-mediated uptake of various lipids into cells. Influence of the nature of the donor particle interaction with the receptor. J. Biol. Chem. 2001, 276, 43801-43808.
121. Yancey, P.G.; de la Llera-Moya, M.; Swarnakar, S.; Monzo, P.; Klein, S.M.; Connelly, M.A.; Johnson, W.J.; Williams, D.L.; Rothblat, G.H. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J. Biol. Chem. 2000, 275, 36596-36604.
122. Werder, M.; Han, C.H.; Wehrli, E.; Bimmler, D.; Schulthess, G.; Hauser, H. Role of scavenger receptors SR-BI and CD36 in selective sterol uptake in the small intestine. Biochemistry 2001, 40, 11643-11650.
123. Urban, S.; Zieseniss, S.; Werder, M.; Hauser, H.; Budzinski, R.; Engelmann, B. Scavenger receptor BI transfers major lipoprotein-associated phospholipids into the cells. J. Biol. Chem. 2000, 275, 33409-33415.
124. Berrougui, H.; Khalil, A. Age-associated decrease of high-density lipoprotein-mediated reverse cholesterol transport activity. Rejuvenation Res. 2009, 12, 117-126.
125. Berrougui, H.; Isabelle, M.; Cloutier, M.; Grenier, G.; Khalil, A. Age-related impairment of HDL-mediated cholesterol efflux. J. Lipid Res. 2007, 48, 328-336.
126. Schriewer, H.; Gunnewig, V.; Assmann, G. HDL sphingomyelin determinations in normal individuals and patients with type IV-hyperlipoproteinaemia. J. Clin. Chem. Clin. Biochem. 1983, 21, 139-143.
127. Deevska, G.M.; Sunkara, M.; Morris, A.J.; Nikolova-Karakashian, M.N. Characterization of secretory sphingomyelinase activity, lipoprotein sphingolipid content and LDL aggregation in ldlr-/- mice fed on a high-fat diet. Biosci. Rep. 2012, 32, 479-490.
128. Bladergroen, B.A.; Beynen, A.C.; Geelen, M.J. Dietary pectin lowers sphingomyelin concentration in VLDL and raises hepatic sphingomyelinase activity in rats. J. Nutr. 1999, 129, 628-633.
129. Geelen, M.J.; van Hoorn, D.; Beynen, A.C. Consumption of casein instead of soybean protein produces a transient rise in the concentration of sphingomyelin in VLDL in rats. J. Nutr. 1999, 129, 2119-2122.
130. Geelen, M.J.; Beynen, A.C. Consumption of olive oil has opposite effects on plasma total cholesterol and sphingomyelin concentrations in rats. Br. J. Nutr. 2000, 83, 541-547.
131. Martínez-Beamonte, R.; Navarro, M.A.; Acin, S.; Guillén, N.; Barranquero, C.; Arnal, C.; Surra, J.; Osada, J. Postprandial changes in high density lipoproteins in rats subjected to gavage administration of virgin olive oil. PLoS One 2013, doi:10.1371/journal.pone.0055231
132. Li, Z.; Basterr, M.J.; Hailemariam, T.K.; Hojjati, M.R.; Lu, S.; Liu, J.; Liu, R.; Zhou, H.; Jiang, X.C. The effect of dietary sphingolipids on plasma sphingomyelin metabolism and atherosclerosis. Biochim. Biophys. Acta 2005, 1735, 130-134.
133. Vesper, H.; Schmelz, E.M.; Nikolova-Karakashian, M.N.; Dillehay, D.L.; Lynch, D.V.; Merrill, A.H., Jr. Sphingolipids in food and the emerging importance of sphingolipids to nutrition. J. Nutr. 1999, 129, 1239-1250.
134. Gerasimova, E.; Perova, N.; Ozerova, I.; Polessky, V.; Metelskaya, V.; Sherbakova, I.; Levachev, M.; Kulakova, S.; Nikitin, Y.; Astakhova, T. The effect of dietary n-3 polyunsaturated fatty acids on HDL cholesterol in Chukot residents vs muscovites. Lipids 1991, 26, 261-265.
135. Myher, J.J.; Kuksis, A.; Shepherd, J.; Packard, C.J.; Morrisett, J.D.; Taunton, O.D.; Gotto, A.M. Effect of saturated and unsaturated fat diets on molecular species of phosphatidylcholine and sphingomyelin of human plasma lipoproteins. Biochim. Biophys. Acta 1981, 666, 110-119.
136. Sola, R.; Baudet, M.F.; Motta, C.; Maille, M.; Boisnier, C.; Jacotot, B. Effects of dietary fats on the fluidity of human high-density lipoprotein: influence of the overall composition and phospholipid fatty acids. Biochim. Biophys. Acta 1990, 1043, 43-51.
137. Ottestad, I.; Hassani, S.; Borge, G.I.; Kohler, A.; Vogt, G.; Hyotylainen, T.; Oresic, M.; Bronner, K.W.; Holven, K.B.; Ulven, S.M.; Myhrstad, M.C. Fish oil supplementation alters the plasma lipidomic profile and increases long-chain PUFAs of phospholipids and triglycerides in healthy subjects. PLoS One 2012, 7, e42550.
138. Tynkkynen, T.; Mursu, J.; Nurmi, T.; Tuppurainen, K.; Laatikainen, R.; Soininen, P. NMR protocol for determination of oxidation susceptibility of serum lipids and application of the protocol to a chocolate study. Metabolomics 2012, 8, 386-398.
139. Floegel, A.; Stefan, N.; Yu, Z.; Muhlenbruch, K.; Drogan, D.; Joost, H.G.; Fritsche, A.; Haring, H.U.; Hrabe de Angelis, M.; Peters, A.; et al. Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach. Diabetes 2013, 62, 639-648.
140. Schriewer, H.; Gunnewig, V.; Jung, K.; Assmann, G. The influence of a 100 km run on the composition of HDL. J. Clin. Chem. Clin. Biochem. 1982, 20, 533-536.
141. Marmillot, P.; Munoz, J.; Patel, S.; Garige, M.; Rosse, R.B.; Lakshman, M.R. Long-term ethanol consumption impairs reverse cholesterol transport function of high-density lipoproteins by depleting high-density lipoprotein sphingomyelin both in rats and in humans. Metabolism 2007, 56, 947-953.
142. Bagdade, J.D.; Dunn, F.L. Improved lipoprotein surface and core lipid composition following intraperitoneal insulin delivery in insulin-dependent diabetes mellitus. Diab. Metab. 1996, 22, 420-426.
143. Bagdade, J.D.; Helve, E.; Taskinen, M.R. Effects of continuous insulin infusion therapy on lipoprotein surface and core lipid composition in insulin-dependent diabetes mellitus. Metabolism 1991, 40, 445-449.
144. Piperi, C.; Kalofoutis, C.; Papapanagiotou, A.; Skenderi, C.; Kalofoutis, A. Comparative analysis of oestrogen and raloxifene effects on the phospholipid composition of high density lipoproteins in healthy postmenopausal women. J. Obstet. Gynaecol. 2004, 24, 52-57.
145. Piperi, C.; Kalofoutis, C.; Skenderi, K.; Economidou, O.; Kalofoutis, A. Beneficial effects of raloxifene and atorvastatin on serum lipids and HDL phospholipids levels of postmenopausal women. J. Obstet. Gynaecol. 2004, 24, 414-419.
146. Bergheanu, S.C.; Reijmers, T.; Zwinderman, A.H.; Bobeldijk, I.; Ramaker, R.; Liem, A.H.; van der Greef, J.; Hankemeier, T.; Jukema, J.W. Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: Investigating differential effects among statins. Curr. Med. Res. Opin. 2008, 24, 2477-2487.
147. Perova, N.V.; Ozerova, I.N.; Paramonova, I.V.; Olfer'ev, A.M.; Akhmedzhanov, N.M.; Pavlova, L.I.; Oganov, R.G. Phospholipid composition of high-density lipoproteins reflects lipolysis of triglyceride-rich lipoproteins during hyperlipidemia. Bull. Exp. Biol. Med. 2001, 131, 321-324.
148. Hammad, S.M. Blood sphingolipids in homeostasis and pathobiology. Adv. Exp. Med. Biol. 2011, 721, 57-66.
149. Yetukuri, L.; Huopaniemi, I.; Koivuniemi, A.; Maranghi, M.; Hiukka, A.; Nygren, H.; Kaski, S.; Taskinen, M.R.; Vattulainen, I.; Jauhiainen, M.; et al. High density lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the FIELD substudy. PLoS One 2011, 6, e23589.
150. Bagdade, J.D.; Buchanan, W.F.; Pollare, T.; Lithell, H. Effects of hydrochlorothiazide and captopril on lipoprotein lipid composition in patients with essential hypertension. Eur. J. Clin. Pharmacol. 1996, 49, 355-359.
151. Bagdade, J.D.; Subbaiah, P.V. Influence of low estrogen-containing oral contraceptives on lipoprotein phospholipid composition and mononuclear cell membrane fluidity. J. Clin. Endocrinol. Metab. 1988, 66, 857-861.
152. Papapanagiotou, A.; Koufali, M.M.; Zachari, A.; Charalabidou, C.; Kalofoutis, A. Effects of hormone replacement therapy on the phospholipid composition of high density lipoproteins in postmenopausal women. J. Obstet. Gynaecol. 2001, 21, 56-61.
153. von Eckardstein, A.; Crook, D.; Elbers, J.; Ragoobir, J.; Ezeh, B.; Helmond, F.; Miller, N.; Dieplinger, H.; Bennink, H.C.; Assmann, G. Tibolone lowers high density lipoprotein cholesterol by increasing hepatic lipase activity but does not impair cholesterol efflux. Clin. Endocrinol. 2003, 58, 49-58.
154. Park, T.S.; Panek, R.L.; Mueller, S.B.; Hanselman, J.C.; Rosebury, W.S.; Robertson, A.W.; Kindt, E.K.; Homan, R.; Karathanasis, S.K.; Rekhter, M.D. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2004, 110, 3465-3471.
155. Lan, W.; Zhu, H.; Zhou, Z.; Ye, C.; Liu, M. 1H NMR investigation on interaction between ibuprofen and lipoproteins. Chem. Phys. Lipids 2007, 148, 105-111.
156. Jones, J.W.; Ways, P. Abnormalities of high density lipoproteins in abetalipoproteinemia. J. Clin. Invest. 1967, 46, 1151-1161.
157. Barenholz, Y.; Yechiel, E.; Cohen, R.; Deckelbaum, R.J. Importance of cholesterol-phospholipid interaction in determining dynamics of normal and abetalipoproteinemia red blood cell membrane. Cell. Biophys. 1981, 3, 115-126.
158. Herbert, P.N.; Hyams, J.S.; Bernier, D.N.; Berman, M.M.; Saritelli, A.L.; Lynch, K.M.; Nichols, A.V.; Forte, T.M. Apolipoprotein B-100 deficiency. Intestinal steatosis despite apolipoprotein B-48 synthesis. J. Clin. Invest. 1985, 76, 403-412.
159. Leventhal, A.R.; Chen, W.; Tall, A.R.; Tabas, I. Acid sphingomyelinase-deficient macrophages have defective cholesterol trafficking and efflux. J. Biol. Chem. 2001, 276, 44976-44983.
160. Dastani, Z.; Ruel, I.L.; Engert, J.C.; Genest, J., Jr.; Marcil, M. Sphingomyelin phosphodiesterase-1 (SMPD1) coding variants do not contribute to low levels of high-density lipoprotein cholesterol. BMC Med. Genet. 2007, 8, 79.
161. Dubois, G.; Mussini, J.M.; Auclair, M.; Battesti, J.; Boutry, J.M.; Kemeny, J.L.; Maziere, J.C.; Turpin, J.C.; Hauw, J.J. Adult sphingomyelinase deficiency: report of 2 patients who initially presented with psychiatric disorders. Neurology 1990, 40, 132-136.
162. Lee, C.Y.; Lesimple, A.; Larsen, A.; Mamer, O.; Genest, J. ESI-MS quantitation of increased sphingomyelin in Niemann-Pick disease type B HDL. J. Lipid Res. 2005, 46, 1213-1228.
163. Lee, C.Y.; Krimbou, L.; Vincent, J.; Bernard, C.; Larramee, P.; Genest, J., Jr.; Marcil, M. Compound heterozygosity at the sphingomyelin phosphodiesterase-1 (SMPD1) gene is associated with low HDL cholesterol. Hum. Genet. 2003, 112, 552-562.
164. Lee, C.Y.; Lesimple, A.; Denis, M.; Vincent, J.; Larsen, A.; Mamer, O.; Krimbou, L.; Genest, J.; Marcil, M. Increased sphingomyelin content impairs HDL biogenesis and maturation in human Niemann-Pick disease type B. J. Lipid Res. 2006, 47, 622-632.
165. Tamasawa, N.; Takayasu, S.; Murakami, H.; Yamashita, M.; Matsuki, K.; Tanabe, J.; Matsui, J.; Satoh, K.; Suda, T. Reduced cellular cholesterol efflux and low plasma high-density lipoprotein cholesterol in a patient with type B Niemann-Pick disease because of a novel SMPD-1 mutation. J. Clin. Lipidol. 2012, 6, 74-80.
166. Yao, J.K.; Herbert, P.N.; Fredrickson, D.S.; Ellefson, R.D.; Heinen, R.J.; Forte, T.; Dyck, P.J. Biochemical studies in a patient with a Tangier syndrome. J. Neuropathol. Exp. Neurol. 1978, 37, 138-154.
167. Pruzanski, W.; Stefanski, E.; de Beer, F.C.; de Beer, M.C.; Ravandi, A.; Kuksis, A. Comparative analysis of lipid composition of normal and acute-phase high density lipoproteins. J. Lipid Res. 2000, 41, 1035-1047.
168. Papathanasiou, A.; Kostara, C.; Cung, M.T.; Seferiadis, K.; Elisaf, M.; Bairaktari, E.; Goudevenos, I.A. Analysis of the composition of plasma lipoproteins in patients with extensive coronary heart disease using 1H NMR spectroscopy. Hellenic J. Cardiol. 2008, 49, 72-78.
169. Bagdade, J.D.; Subbaiah, P.V. Abnormal high-density lipoprotein composition in women with insulin-dependent diabetes. J. Lab. Clin. Med. 1989, 113, 235-240.
170. Bagdade, J.D.; Subbaiah, P.V. Whole-plasma and high-density lipoprotein subfraction surface lipid composition in IDDM men. Diabetes 1989, 38, 1226-1230.
171. Chapkin, R.S.; Haberstroh, B.; Liu, T.; Holub, B.J. Characterization of the individual phospholipids and their fatty acids in serum and high-density lipoprotein of the renal patient on long-term maintenance hemodialysis. J. Lab. Clin. Med. 1983, 101, 726-735.
172. Makinen, V.P.; Tynkkynen, T.; Soininen, P.; Peltola, T.; Kangas, A.J.; Forsblom, C.; Thorn, L.M.; Kaski, K.; Laatikainen, R.; Ala-Korpela, M.; et al. Metabolic diversity of progressive kidney disease in 325 patients with type 1 diabetes (the FinnDiane Study). J. Proteome Res. 2012, 11, 1782-1790.
173. Makinen, V.P.; Tynkkynen, T.; Soininen, P.; Forsblom, C.; Peltola, T.; Kangas, A.J.; Groop, P.H.; Ala-Korpela, M. Sphingomyelin is associated with kidney disease in type 1 diabetes (The FinnDiane Study). Metabolomics 2012, 8, 369-375.
174. Kuliszkiewicz-Janus, M.; Baczynski, S. Chemotherapy-associated changes in 31P MRS spectra of sera from patients with multiple myeloma. NMR Biomed. 1995, 8, 127-132.
175. Pussinen, P.J.; Jauhiainen, M.; Vilkuna-Rautiainen, T.; Sundvall, J.; Vesanen, M.; Mattila, K.; Palosuo, T.; Alfthan, G.; Asikainen, S. Periodontitis decreases the antiatherogenic potency of high density lipoprotein. J. Lipid Res. 2004, 45, 139-147.
176. Ozerova, I.N.; Perova, N.V.; Shchel'tsyna, N.V.; Mamedov, M.N. Parameters of high-density lipoproteins in patients with arterial hypertension in combination with other components of metabolic syndrome. Bull. Exp. Biol. Med. 2007, 143, 320-322.
177. Francone, O.L.; Subbaiah, P.V.; van Tol, A.; Royer, L.; Haghpassand, M. Abnormal phospholipid composition impairs HDL biogenesis and maturation in mice lacking Abca1. Biochemistry 2003, 42, 8569-8578.
178. Jeong, T.; Schissel, S.L.; Tabas, I.; Pownall, H.J.; Tall, A.R.; Jiang, X. Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. J. Clin. Invest. 1998, 101, 905-912.
179. Dong, J.; Liu, J.; Lou, B.; Li, Z.; Ye, X.; Wu, M.; Jiang, X.C. Adenovirus-mediated overexpression of sphingomyelin synthases 1 and 2 increases the atherogenic potential in mice. J. Lipid Res. 2006, 47, 1307-1314.
180. Wang, X.; Dong, J.; Zhao, Y.; Li, Y.; Wu, M. Adenovirus-mediated sphingomyelin synthase 2 increases atherosclerotic lesions in ApoE KO mice. Lipids Health Dis. 2011, 10, 7.
181. Siggins, S.; Bykov, I.; Hermansson, M.; Somerharju, P.; Lindros, K.; Miettinen, T.A.; Jauhiainen, M.; Olkkonen, V.M.; Ehnholm, C. Altered hepatic lipid status and apolipoprotein A-I metabolism in mice lacking phospholipid transfer protein. Atherosclerosis 2007, 190, 114-123.
182. Li, Z.; Li, Y.; Chakraborty, M.; Fan, Y.; Bui, H.H.; Peake, D.A.; Kuo, M.S.; Xiao, X.; Cao, G.; Jiang, X.C. Liver-specific deficiency of serine palmitoyltransferase subunit 2 decreases plasma sphingomyelin and increases apolipoprotein E levels. J. Biol. Chem. 2009, 284, 27010-27019.